Traders should monitor upcoming target engagement data for AX-0810 this quarter as a near-term catalyst; the expansion of the pipeline supports longer-term value, but no financial or efficacy data was released.
Price Chart
Executive Summary
ProQR Therapeutics provided a pipeline update highlighting progress on its lead program AX-0810, with target engagement data expected this quarter, and announced biliary atresia as the initial Phase 2 indication. The company also unveiled two new clinical-stage programs, AX-0811 and AX-0422, with clinical data readouts anticipated through 2027, all within its current cash runway extending to mid-2027.
Key Facts
- AX-0810 target engagement data in healthy volunteers expected in H1 2026 (this quarter)
- Biliary atresia selected as initial Phase 2 indication for AX-0810
- AX-0811 (next-gen NTCP program) CTA filing expected mid-2026, initial data by year-end 2026
- AX-0422 (Hurler syndrome) CTA filing expected early 2027, initial data H1 2027
- AX-2911 (MASH) FIH trial planned in China H1 2027
- Cash runway extends into mid-2027
Financial Impact
No immediate financial impact; updates are pipeline and timeline-driven
Risk Factors
- Clinical data delays or negative results could impact valuation
- Dilution risk if additional funding is required before mid-2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270485 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.68% | $1.29 (−24.12%) |
Sep 9, 2026 6w ago | 6-K | $1.99 $1.86 | ▼ −6.53% | ▼ −5.44% | $1.29 (−35.18%) |
Jul 16, 2026 14w ago | EFFECT | $1.67 $1.79 | ▼ −7.19% | ▼ −8.86% | $1.29 (+22.75%) |
Jun 25, 2026 17w ago | 6-K | $1.53 $1.81 | ▼ −18.30% | ▼ −16.13% | $1.29 (+15.69%) |
Jun 25, 2026 17w ago | 424B5 | $1.53 $1.81 | ▲ +18.30% | ▲ +16.13% | $1.29 (−15.69%) |
Jun 2, 2026 20w ago | 6-K | $1.47 $1.41 | ▼ −4.08% | ▼ −0.26% | $1.29 (−12.24%) |
May 12, 2026 23w ago | 6-K | $1.60 $1.51 | ▲ +5.63% | ▲ +5.70% | $1.29 (+19.38%) |
Apr 30, 2026 25w ago | 6-K | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.29 (−17.83%) |
Apr 30, 2026 25w ago | Press Release | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.29 (−17.83%) |
Apr 8, 2026 28w ago | 6-K | $1.98 $1.95 | ▼ −1.52% | ▼ −4.70% | $1.29 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers